Anbio Biotechnology Class A Ordinary Shares (NNNN) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | 1.6M | 647.54K | -1.33M | 2.3M |
| Operating CF Margin % | 63.46% | 10.24% | -33.71% | 69.67% |
| Operating CF Growth % | 220.49% | -71.89% | - | - |
| Net Income | -1.32M | 3.89M | 792.93K | 1.64M |
| Depreciation & Amortization | 0 | 0 | 3.54K | 9.49K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -209.64K | -149.34K | -157.43K | -17.68K |
| Working Capital Changes | 3.14M | -3.09M | -1.97M | 668.35K |
| Change in Receivables | 3.84M | -2.95M | -2.04M | 0 |
| Change in Inventory | 0 | 0 | 373 | 382.39K |
| Change in Payables | 1.24M | -376.34K | -520.15K | -108.17K |
| Cash from Investing | 215.57K | 149.34K | 160.7K | 1.71M |
| Capital Expenditures | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | 0% | 0% | 0% | 0% |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | -248.89K | -124.14K | 230.08K | -276.41K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | -248.89K | -124.14K | 230.08K | -276.41K |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 |
| Net Change in Cash | 0 | 0 | 0 | 0 |
| Free Cash Flow | 1.6M | 647.54K | -1.33M | 2.3M |
| FCF Margin % | 63.46% | 10.24% | -33.71% | 69.67% |
| FCF Growth % | 220.49% | -71.89% | - | - |
| FCF per Share | 0.04 | 0.02 | -0.03 | 0.05 |
| FCF Conversion (FCF/Net Income) | -1.21x | 0.17x | -1.68x | 1.40x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |